FDA 483 - Ionetix Corporation - September 14, 2023

An FDA inspection of Ionetix Corporation, a PET drug manufacturer in El Paso, TX, revealed two significant observations. The firm's facilities were found inadequate for preventing contamination due to a lack of viable surface sampling in critical sterile areas. Additionally, laboratory testing procedures were deficient, specifically regarding the validation of incubation parameters for environmental and personnel monitoring.